MedTrace Logo

Improved Diagnostics and Monitoring of Polymyalgia Rheumatica

NCT04519580 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2025-09-24

No results posted yet for this study

Summary

Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects. PMR is an exclusion diagnosis, and methods to diagnose and monitor the disease are lacking.

Objective: To investigate if ultrasound and PET/CT can be used to diagnose and monitor PMR. In addition, the importance of prednisolone induced adrenal insufficiency is investigated.

Methods: It is a prospective observational study in patients suspected of PMR. Patients diagnosed with PMR continue in the study. Ultrasound and PET/CT are performed at baseline, after 8 weeks on prednisolone, and after 10 weeks during a short prednisolone break. Adrenal insufficiency is investigated five times throughout the study. After one year the PMR diagnosis is confirmed.

Conditions

Interventions

DIAGNOSTIC_TEST

PET/CT

FDG-PET/CT at baseline, week 8 and week 10.

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Kresten Krarup Keller

    lead OTHER

Principal Investigators

  • Kresten Keller, MD · Department of Rheumatology, Aarhus University Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2023-07-04
Completion
2027-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04519580 on ClinicalTrials.gov